General Electric: Head-to-Head study reports patient comfort with Visipaque (iodixanol) and Isovue (iopamidol) during peripheral arteriography; results of comparative study suggest that Visipaque may be a preferable contrast agent for use in peripheral arteriography (GE) : Co announced results from a new study, which showed that patients receiving Visipaquetm (iodixanol) 320mg I/ml reported less discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving Isovue (iopamidol) 370 mg I/ml during peripheral arteriography. As with other iodinated contrast agents, Visipaque is often associated with sensations of discomfort, warmth or pain. The data were presented at the American College of Cardiology's 63rd Annual Scientific Session and Expo. While this study was not powered to detect a difference in image quality, the number of subjects with image quality rated as excellent was numerically greater in the Visipaque group (86.5%) versus the Isovue group (82.4%), but the difference was not statistically significant. Discomfort impacted image quality in 6.5% of Isovue subject images and in 3.2% of Visipaque subject images.